Kyverna Therapeutics, Inc. Common Stock (KYTX) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Kyverna Therapeutics, Inc. Common Stock (US:KYTX), currently being evaluated. In 2022, Kyverna Therapeutics, Inc. Common Stock generated $7.03 Million in revenue and -$36.88 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Kyverna Therapeutics, Inc. Common Stock is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2022): $7.03 Million
- Free Cash Flow (2022): -$36.88 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.